Management of Hyperkalemia in an Emergency Situation: Best Practices Recommendations Driven by Consensus Methodology
Gestão da Hipercalemia em Contexto de Urgência: Recomendações de Boas Práticas Geradas por Metodologia de Consenso
DOI:
https://doi.org/10.24950/rspmi.2527Keywords:
Consensus, Delphi Technique, Hyperkalemia/ diagnosis, Hyperkalemia/drug therapy, Polymers, Potassium, Renin-Angiotensin System, SilicatesAbstract
Introduction: Hyperkalemia (HK) is characterized by elevated serum potassium levels and is common in patients
with chronic kidney disease, diabetes mellitus and cardiovascular diseases. Severe hyperkalemia increases the risk of cardiac disturbances and mortality. Real-world studies and international expert groups highlight the urgent need to optimize hyperkalemia management however, consensus in this area is lacking, especially concerning new drugs. We aim to establish a consensus among healthcare professionals in Portugal regarding the effective management of HK in emergency settings. Additionally, we aim to provide recommendations for the adoption of best practices in emergency care.
Methods: This qualitative study was based on Delphi
consensus. A panel of experts collaboratively identified and
discussed five main topics related to HK management and
defined 25 treatment statements. An online questionnaire was distributed to doctors who frequently handle emergencies between July and August 2023. A consensus was defined when at least 65% of respondents indicated agreement or strong agreement with a statement. The initial round produced high agreement levels, obviating the need for additional survey rounds.
Results: A total of 63 specialist doctors participated in the online questionnaire. There was a very high consensus,
with over 90% of participants either agreeing or strongly
agreeing with 19 of the 25 statements. These establish that
HK is a critical concern for patients with chronic kidney disease, particularly those with a lower estimated glomerular filtration rate (eGFR), elderly population and patients on medications such as inhibitor renin-angiotensin–aldosterone system (iRAAS), angiotensin II receptor blockers ( ARBs), mineralocorticoid-receptor antagonists (MRAs), or potassium-sparing diuretics. They also agree that HK is associated with higher mortality risk, which increases in individuals with underlying conditions or prolonged HK. Statements regarding potassium management involving sodium zirconium cyclosilicate (SZC), patiromer, scavengers in patients on iRAAS, and related to insulin treatment had the lowest consensus levels.
Conclusion: A robust consensus among Portuguese
healthcare professionals regarding effective HK management in emergency settings was achieved. Experts collaboratively formulated recommendations covering key aspects of the management of HK in emergency settings. Implementing these recommendations will enhance the delivery of harmonized evidence-based medical care and the improvement of clinical outcomes.
Downloads
References
Gilligan S, Raphael KL. Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes. Adv Chronic Kidney Dis. 2017;24:315-8. doi: 10.1053/j.ackd.2017.06.004.
Mushiyakh Y, Dangaria H, Qavi S, Ali N, Pannone J, Tompkins D. Treatment and pathogenesis of acute hyperkalemia. J Community Hosp Intern Med Perspect. 2012;1. doi: 10.3402/jchimp.v1i4.7372.
Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol. 2019;32:499-516. doi: 10.1007/s40620-019-00617-y.
Gorriz JL, D'Marco L, Pastor-González A, Molina P, Gonzalez-Rico M, Puchades MJ, et al. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia. Nephrol Dial Transplant. 2022;37:522-30. doi: 10.1093/ndt/gfab003.
Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39:1535-42. doi: 10.1093/eurheartj/ehy100.
Rafique Z, Peacock F, Armstead T, Bischof JJ, Hudson J, Weir MR, et al. Hyperkalemia management in the emergency department: An expert panel consensus. J Am Coll Emerg Physicians Open. 2021;2:e12572. doi: 10.1002/emp2.12572.
Weinstein J, Girard LP, Lepage S, McKelvie RS, Tennankore K. Prevention and management of hyperkalemia in patients treated with renin-angiotensinaldosterone system inhibitors. CMAJ. 2021;193:E1836-41. doi: 10.1503/cmaj.210831.
Palmer BF, Carrero JJ, Clegg DJ, Colbert GB, Emmett M, Fishbane S, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96:744-62. doi: 10.1016/j.mayocp.2020.06.014.
Best practices in managing hyperkalemia in chronic kidney disease. In: National Kidney Foundation website [Internet]. [cited 5 Apr 2023]. Available: https://www.kidney.org/sites/default/files/02-10-7259%20Hyperkalemia% 20Tool.pdf
Long B, Warix JR, Koyfman A. Controversies in management of hyperkalemia. J Emerg Med. 2018;55:192-205. doi: 10.1016/j.jemermed. 2018.04.004.
Rosano GM, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018;4:180-8. doi: 10.1093/ehjcvp/pvy015.
Mohamed Pakkir Maideen N, Balasubramanian R, Muthusamy S, Nallasamy V. An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers. Curr Cardiol Rev. 2022;18:e110522204611. doi: 10.2174/15734 03X18666220511152330.
Silva-Cardoso J, Brito D, Frazão JM, Ferreira A, Bettencourt P, Branco P, et al. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Fail Rev. 2021;26:891-6. doi: 10.1007/s10741-020-10069-3.
Fravel MA, Meaney CJ, Noureddine L. Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System Inhibitors. Curr Hypertens Rep. 2023;25:395-404. doi: 10.1007/s11906-023-01265-1.
Moussavi K, Fitter S, Gabrielson SW, Koyfman A, Long B. Management of hyperkalemia with insulin and glucose: pearls for the emergency clinician. J Emerg Med. 2019;57:36-42. doi: 10.1016/j.jemermed.2019.03.043.
Kijprasert W, Tarudeeyathaworn N, Loketkrawee C, Pimpaporn T, Pattarasettaseranee P, Tangsuwanaruk T. Predicting hypoglycemia after treatment of hyperkalemia with insulin and glucose (Glu-K60 score). BMC Emerg Med. 2022;22:179. doi: 10.1186/s12873-022-00748-9.
Lott C, Truhlár A, Alfonzo A, Barelli A, González-Salvado V, Hinkelbein J, et al. ERC Special Circumstances Writing Group Collaborators. European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances. Resuscitation. 2021;161:152-219. doi: 10.1016/j.resuscitation. 2021.02.011. Erratum in: Resuscitation. 2021;167:91-92.
De Nicola L, Ferraro PM, Montagnani A, Pontremoli R, Dentali F, Sesti G. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors. Intern Emerg Med. 2023;19:295-306. doi: 10.1007/s11739-023-03427-0.
Burton JO, Coats AJS, Kovesdy CP, Palmer BF, Piña IL, Rosano G, et al. An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum. Eur J Heart Fail. 2022;2:1467-77. doi: 10.1002/ejhf.2612
Downloads
Published
How to Cite
License
Copyright (c) 2023 Internal Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna